The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
Cai Y, Yan X, Zhang G, Zhao W, Jiao S, Jiao S.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.3620 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för panobinostat. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
18 hitsAn HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation.
Meng Q, Liu Z, Li F, Ma J, Wang H, Huan Y, Li Z.
Mol Pharm · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.molpharmaceut.5b00167Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, San-Miguel JF.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/14737140.2015.1047770The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.
Høgh Kølbæk Kjær AS, Brinkmann CR, Dinarello CA, Olesen R, Østergaard L, Søgaard OS, Tolstrup M, Rasmussen TA.
AIDS · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1097/qad.0000000000000678Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
Savelieva M, Woo MM, Schran H, Mu S, Nedelman J, Capdeville R.
Eur J Clin Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s00228-015-1846-7Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.
Gao L, Gao M, Yang G, Tao Y, Kong Y, Yang R, Meng X, Ai G, Wei R, Wu H, Wu X, Shi J.
Biomed Res Int · research support, non-u.s. gov't; research-article; journal article · DOI 10.1155/2015/459052Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S.
Breast Cancer Res Treat · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s10549-015-3376-5Panobinostat: first global approval.
Garnock-Jones KP.
Drugs · review; journal article · DOI 10.1007/s40265-015-0388-8Panobinostat approved for multiple myeloma.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2015-040Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW.
Haematologica · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.3324/haematol.2014.119735Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.
Salmon JM, Bots M, Vidacs E, Stanley KL, Atadja P, Zuber J, Johnstone RW.
Clin Epigenetics · research-article; journal article · DOI 10.1186/s13148-014-0034-4Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H, Hrzenjak A.
Mol Cancer · research-article; journal article · DOI 10.1186/1476-4598-14-4Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.
Neuro Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1093/neuonc/nou350Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra J.
Leuk Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.leukres.2014.12.014Panobinostat: a review of trial results and future prospects in multiple myeloma.
Libby EN, Becker PS, Burwick N, Green DJ, Holmberg L, Bensinger WI.
Expert Rev Hematol · review; journal article · DOI 10.1586/17474086.2015.983065A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S.
Cancer Chemother Pharmacol · multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-014-2612-8Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, Ge Y.
Cancer Lett · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.canlet.2014.10.015DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells.
Pont LM, Naipal K, Kloezeman JJ, Venkatesan S, van den Bent M, van Gent DC, Dirven CM, Kanaar R, Lamfers ML, Leenstra S.
Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2014.09.049